Increasing use of gonadotropin-releasing hormone agonists for the treatment of localized prostate carcinoma

摘要: BACKGROUND The role of androgen deprivation therapy in prostate carcinoma is controversial earlier stages disease. The authors examined the time trends and patterns use for form gonadotropin-releasing hormone (GnRH) agonists or orchiectomy, population-based tumor registries. METHODS Data were obtained from linked Surveillance, Epidemiology End Results-Medicare database. A total 100,274 men with diagnosed 1991 through 1999 selected. main outcome was proportion who received ≥ 1 dose a GnRH agonist first 6 months diagnosis. This plotted by year stratified age, grade, stage as well primary versus adjuvant usage. Multiple logistic regression used to examine predictors subset patients localized cancer. RESULTS There consistent increase all ages, stages, grades. Even 80 years low moderate grade tumors, increased over study period, 3.7% 30.9% (P < 0.001). multivariable analysis showed that significant variability existed among SEER geographic regions. CONCLUSIONS The dramatically during 1990s. occurred across histologic grades carcinoma, greatest years. Cancer 2005. © 2005 American Society.